has received a Notice of Compliance (NOC)from Health Canada for its generic Semaglutide injection.
Dr. Reddy’s becomes the first company to receive the market authorization for generic Semaglutide Injection* in Canada, ahead of Health Canada’s review target date.
The market authorization covers the 2 mg / pen (1.34 mg / mL) and 4 mg / pen (1.34 mg / mL). With launch preparations underway, Dr. Reddy’s is “well-positioned” to bring this important treatment option available to Canadian patients, the Hyderabad-based company said on Wednesday.
Erez Israeli, Chief Executive Officer, Dr. Reddy’s, said: “The approval of our generic Semaglutide Injection by Health Canada represents a significant milestone in our GLP-1 journey and underscoresour expertise in complex product development, peptide science, and our ability to meet stringent global regulatory standards. Canada remains a priority market for us. “
“As the first company to receive market authorization for generic Semaglutide Injection in Canada, we remain dedicated to expanding access to innovative, high‑quality, affordable GLP‑1 treatments for patients,” he added.
As per Public Health Agency of Canada, around 3.9 million people (9.7% of the population) in Canada over a year old live with diagnosed diabetes. In addition, over 6% of adults in Canada live with prediabetes, which gives them a higher chance of developing type 2 diabetes. The number of people living with diabetes is expected to continue to increase as Canada’s population ages and grows.